Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global Parathyroid Disorders market size was valued at USD 2.1 billion in 2024. The market is projected to grow from USD 2.25 billion in 2025 to USD 3.5 billion by 2032, exhibiting a CAGR of 5.8% during the forecast period.
Parathyroid disorders are medical conditions resulting from the dysfunction of the parathyroid glands, four small glands located in the neck that regulate the body's calcium levels. These disorders lead to abnormal calcium levels in the blood, which can cause significant health issues such as brittle bones (osteoporosis), kidney stones, chronic fatigue, and muscle weakness. The primary disorders include hyperparathyroidism (overactive glands), hypoparathyroidism (underactive glands), and the rare parathyroid cancer.
Market growth is primarily driven by an aging global population more susceptible to these conditions and the rising prevalence of chronic kidney disease (CKD), a major cause of secondary hyperparathyroidism. Furthermore, advancements in diagnostic techniques, such as more sensitive parathyroid hormone (PTH) assays, are facilitating earlier and more accurate detection. Key players like Amgen, with its calcimimetic drug Cinacalcet, and Abbott Laboratories, a leader in diagnostic solutions, are actively shaping the treatment landscape through innovation and strategic initiatives, contributing to market expansion.
Aging Population and Rising Disease Prevalence
The global increase in the geriatric population is a primary driver for the parathyroid disorders market, as individuals over 60 are at a significantly higher risk for conditions like primary hyperparathyroidism. Concurrently, improved diagnostic capabilities and greater awareness among both physicians and patients are leading to earlier and more frequent detection of these disorders, thus expanding the diagnosed patient pool.
Technological Advancements in Diagnostics and Treatment
Innovations in medical technology are profoundly impacting the market. The adoption of highly sensitive intraoperative parathyroid hormone (IOPTH) monitoring and advanced preoperative imaging techniques like 4D-CT and sestamibi SPECT scans have increased the success rates of minimally invasive parathyroidectomies. These advancements lead to shorter hospital stays and lower complication rates, driving procedural volume and associated device and pharmaceutical markets.
➤ The expanding use of minimally invasive surgical techniques has become the standard of care for primary hyperparathyroidism, supported by clinical guidelines.
Furthermore, the development of new pharmaceutical options, such as calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients, provides non-surgical treatment pathways, increasing the addressable market beyond surgical candidates.
MARKET CHALLENGES
High Cost of Treatment and Diagnostic Procedures
The advanced imaging and surgical technologies that drive the market also present a significant financial challenge. Procedures like minimally invasive parathyroidectomy and the requisite preoperative localization studies are costly. In many healthcare systems, budget constraints and complex reimbursement policies can limit patient access to these optimal treatments, particularly in developing regions.
Other Challenges
Diagnostic Delays and Misdiagnosis
Parathyroid disorders often present with non-specific symptoms such as fatigue, bone pain, and cognitive issues, which can be mistaken for more common conditions. This frequently leads to significant delays in accurate diagnosis, sometimes for years, impacting patient outcomes and delaying treatment initiation, which affects market growth.
Limited Awareness and Clinical Expertise
A lack of widespread awareness about parathyroid disorders among primary care physicians and the general public remains a hurdle. Furthermore, the management of these conditions, especially complex cases, requires specialized endocrinologists and endocrine surgeons, whose numbers are insufficient in many geographic areas, creating a treatment gap.
Stringent Regulatory Hurdles for New Therapies
The development and approval process for new drugs and medical devices targeting parathyroid disorders is lengthy and expensive, governed by strict regulatory bodies like the FDA and EMA. The requirement for extensive clinical trials demonstrating safety and efficacy for often small patient populations acts as a significant barrier to market entry for new players and innovation.
Economic and Healthcare Infrastructure Disparities
Market growth is restrained by the vast disparities in healthcare infrastructure and economic development across different regions. Access to modern diagnostic tools and specialized surgical care is predominantly concentrated in high-income countries, significantly limiting the market's potential in emerging economies where healthcare spending is prioritized for more prevalent infectious and chronic diseases.
Expansion into Emerging Markets
There is substantial untapped potential in emerging economies across Asia, Latin America, and the Middle East. Rising healthcare expenditure, growing medical tourism for complex surgeries, and increasing local healthcare infrastructure development present significant opportunities for market expansion for pharmaceutical and medical device companies.
Development of Novel Therapeutics and Diagnostics
The market offers considerable opportunity for the development of more effective and convenient therapeutic options, such as longer-acting calcimimetics or novel drug classes. Additionally, there is a growing need for more accurate, non-invasive, and cost-effective diagnostic tools, which could revolutionize disease screening and monitoring, creating new revenue streams.
Focus on Personalized Medicine
The trend towards personalized medicine opens avenues for growth. Opportunities exist in developing targeted therapies based on genetic markers and creating tailored treatment plans that improve outcomes for specific patient subgroups, such as those with familial forms of hyperparathyroidism or refractory disease.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Hyperparathyroidism represents the leading segment within the parathyroid disorders market due to its higher prevalence, particularly the asymptomatic form which requires long-term monitoring and management strategies. The complexity of the disease, often linked to chronic kidney conditions causing secondary hyperparathyroidism, necessitates a comprehensive and sustained therapeutic approach. This drives ongoing demand for diagnostic evaluations and treatment modalities, including parathyroidectomy for symptomatic cases, establishing a robust and continuous market presence. |
| By Application |
|
Hospitals are the dominant application segment, serving as the primary point of care for managing parathyroid disorders. Their central role is driven by the need for complex procedures like parathyroidectomy, comprehensive diagnostic capabilities including serum calcium and PTH level testing, and the management of associated complications such as kidney stones and brittle bones. The multidisciplinary environment of hospitals is essential for the integrated care of patients, especially those with comorbidities like chronic kidney disease, reinforcing their leading market position. |
| By End User |
|
Healthcare Providers constitute the leading end-user segment, as they are the principal decision-makers for treatment pathways, diagnostic protocols, and pharmaceutical prescriptions. This group, including endocrinologists and nephrologists, requires a continuous supply of medications like calcitriol for hypoparathyroidism and access to surgical options, driving significant market demand. The reliance on their expertise for long-term patient management and monitoring of conditions ensures a consistent and substantial influence on the market ecosystem. |
| By Treatment Modality |
|
Pharmacological Therapy is the leading segment, primarily due to the chronic nature of many parathyroid disorders requiring lifelong management. For hypoparathyroidism, continuous vitamin D and calcium replacement therapy is essential, while secondary hyperparathyroidism in chronic kidney disease patients involves complex drug regimens. This creates a stable and recurring demand for pharmaceuticals, making it a cornerstone of the treatment landscape compared to the one-time nature of surgical interventions for many patients. |
| By Diagnostic Method |
|
Biochemical Testing is the dominant diagnostic segment, forming the initial and ongoing foundation for identifying and managing parathyroid disorders. The standard evaluation involves repeat measurements of serum calcium, parathyroid hormone, creatinine, and vitamin D levels, which are critical for diagnosis, differential diagnosis, and monitoring treatment efficacy. The essential and recurrent nature of these tests for patient management, from initial workup to long-term surveillance, ensures this segment's fundamental and leading role in the diagnostic market. |
A Mix of Pharmaceutical Giants and Medical Device Specialists
The competitive landscape of the parathyroid disorders market is characterized by the involvement of large, diversified pharmaceutical and medical technology companies with significant resources for research and development. These players develop and market therapies for conditions like hypoparathyroidism, medications for managing complications of hyperparathyroidism such as chronic kidney disease-mineral and bone disorder (CKD-MBD), and surgical instruments used in parathyroidectomy procedures. Market leadership is fragmented, with no single company holding a dominant share, but entities like Amgen, with its blockbuster drug for secondary hyperparathyroidism, and Abbott Laboratories, a leader in diagnostic testing, represent significant forces. The market structure is influenced by high barriers to entry due to regulatory hurdles and the need for specialized R&D, leading to a competitive environment focused on innovation in drug formulations and targeted therapeutic approaches.
Beyond the leading players, several other companies hold significant niches. Specialized pharmaceutical firms focus on rare endocrine disorders, developing treatments for hypoparathyroidism, while medical device companies provide critical surgical equipment and diagnostic tools. Companies such as Takeda Pharmaceutical (through its Shire acquisition) and Ascendis Pharma are active in developing hormone replacement therapies. Furthermore, diagnostic companies play a crucial role in the ecosystem by providing assays for measuring parathyroid hormone (PTH) and calcium levels, which are essential for diagnosis and management. This diverse ecosystem includes established giants leveraging their broad portfolios and smaller, agile companies pursuing targeted innovations to address unmet needs in parathyroid care.
List of Key Parathyroid Disorders Companies ProfiledAbbott Laboratories
Bayer Healthcare
Becton, Dickinson and Company
Ethicon (Johnson & Johnson)
Alcon Laboratories (Novartis)
Takeda Pharmaceutical Company Limited
F. Hoffmann-La Roche Ltd
Siemens Healthineers
DiaSorin S.p.A.
OPKO Health, Inc.
Shire (now part of Takeda)
The global market for parathyroid disorders is primarily propelled by the increasing incidence of chronic kidney disease (CKD) worldwide. Patients with CKD frequently develop secondary hyperparathyroidism, a key component of chronic kidney disease-mineral and bone disorder (CKD-MBD). This condition, characterized by abnormal calcium and phosphate metabolism, necessitates ongoing medical management and monitoring, thereby sustaining demand for diagnostic tests and therapeutic interventions. The global market was valued at a significant figure in 2024 and is projected to grow steadily, reaching a multi-million dollar valuation by 2032, reflecting a compound annual growth rate influenced by this underlying demographic trend.
Other TrendsAdvancements in Diagnostic and Surgical Techniques
The evaluation of patients with abnormal serum calcium levels has become more sophisticated, involving a comprehensive assessment including history, physical examination, and precise measurement of serum calcium, creatinine, magnesium, vitamin D, and parathyroid hormone (PTH) levels. This trend towards more precise diagnostics supports early and accurate identification of disorders like primary hyperparathyroidism and hypoparathyroidism. Concurrently, parathyroidectomy remains the definitive treatment for symptomatic primary hyperparathyroidism, with surgical techniques continuously evolving to improve success rates and minimize complications, influencing the market's procedural segment.
There is a notable trend towards the management of asymptomatic primary hyperparathyroidism through vigilant monitoring of symptoms, serum calcium and creatinine levels, and bone mineral density, rather than immediate surgical intervention. For hypoparathyroidism, which often results from neck surgery, the standard of care involves close monitoring and vitamin D replacement therapy, such as calcitriol. Key industry players, including Amgen, Abbott Laboratories, and Bayer Healthcare, are active in this space, focusing on developing and marketing pharmaceuticals and diagnostics. The market is segmented by type, with hyperparathyroidism holding a dominant share, and by application, where hospitals represent the largest end-user segment, particularly in North America and Europe.
Regional Analysis: Parathyroid Disorders MarketEurope
Europe represents a mature and significant market for parathyroid disorders, characterized by well-developed public healthcare systems that facilitate patient access to care. Countries like Germany, France, and the UK have high standards for endocrine disease management, leading to good diagnostic rates. The market is supported by strong academic research and clinical guidelines that standardize care pathways across the region. However, market growth can be influenced by varying reimbursement policies between national health systems, sometimes leading to disparities in access to the latest treatments. There is a growing emphasis on cost-effectiveness, which shapes the adoption of new technologies and pharmaceuticals. Cross-border collaboration in clinical research helps drive innovation, but price controls implemented by some governments can slow the market penetration of premium-priced advanced therapies compared to North America.
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for parathyroid disorders, fueled by improving healthcare infrastructure, rising medical awareness, and increasing healthcare expenditure in major economies like China, India, and Japan. The large patient population presents a substantial opportunity, though diagnosis rates remain relatively low in many areas due to limited access to specialized care in rural regions. Market growth is driven by the expansion of private healthcare and increasing adoption of Western medical practices. Local manufacturing of generic pharmaceuticals and medical devices is making treatments more affordable. However, challenges include significant unmet need, variable quality of care, and the need for greater physician education on parathyroid disorders to improve early detection and management strategies across this diverse region.
South America
The parathyroid disorders market in South America is developing, with growth concentrated in larger economies such as Brazil and Argentina. Access to modern diagnostics and specialized surgical care is primarily available in major urban centers, creating a urban-rural healthcare divide. Economic volatility in some countries can impact public health spending and patients' ability to pay for treatments. The market is characterized by a reliance on imported medical devices and pharmaceuticals, which can lead to higher costs. Efforts are being made to improve healthcare access through government initiatives, but the market growth is moderate compared to more developed regions, hindered by infrastructure limitations and a need for greater specialization in endocrine surgery and medicine.
Middle East & Africa
The Middle East & Africa region exhibits a highly heterogeneous market for parathyroid disorders. Wealthier Gulf Cooperation Council (GCC) countries have advanced medical facilities and high standards of care, often importing cutting-edge technologies and attracting medical tourists. In contrast, many African nations face significant challenges, including limited diagnostic capabilities, a shortage of specialist surgeons, and low awareness of parathyroid conditions. The market is therefore largely driven by a few high-income countries, while broader regional growth is constrained by infrastructural and economic disparities. Philanthropic and international aid programs play a role in building capacity, but the overall market remains nascent with vast unmet medical needs across much of the continent.
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global parathyroid disorders market was valued at USD 2.1 billion in 2024 and is expected to reach USD 3.5 billion by 2032.
Which key companies operate in Global Parathyroid Disorders Market?
-> Key players include Abbott Laboratories, Alcon Laboratories, Amgen, Bayer Healthcare, and Becton, Dickinson and Company, among others.
-> Key growth drivers include aging global population, rising prevalence of chronic kidney disease, and advancements in diagnostic techniques.
-> North America holds the largest market share, while Asia-Pacific is the fastest-growing region.
-> Emerging trends include more sensitive parathyroid hormone (PTH) assays and innovative treatment options like calcimimetic drugs.
Our Clients
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates